Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In this article, we will be taking a look at the 20 countries with the highest rates of stomach cancer in the world. If you do not want to learn about the global cancer trends, head straight to the 5 Countries with the Highest Rates of Stomach Cancer in the World. Overview of the Global […]
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 23, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use.
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in t
The U.S. Food and Drug Administration said it has approved BeiGene's drug to treat a type of advanced esophageal cancer in patients who have previously received chemotherapy. The therapy, branded as Tevimbra, was approved as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma. Tevimbra will be available to U.S. patients in the second half of 2024, a company spokesperson said, adding that it will share pricing details closer to the launch.
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 13, 2024--The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lympho
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 07, 2024--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy. The indication is